INTERNATIONAL PATENT: AITHENUTRIGENE CO., 주식회사 에이아이더뉴트리진 FILES APPLICATION FOR "COMPOSITION FOR DIRECT CELL LYSIS WHICH CAN BE APPLIED TO VARIOUS SPECIMENS AND ENABLES RAPID NUCLEIC ACID PRETREATMENT AND PAPER-BASED ONE-STEP ALL-IN-ONE MOLECULAR DIAGNOSTIC PLATFORM HAVING IMPROVED USER CONVENIENCE, USING SAME"

GENEVA, Oct. 28 -- AITHENUTRIGENE CO. (630, 42, Changeop-ro, Sujeong-gu,Seongnam-si,Gyeonggi-do 13449), 주식회사 에이아이더뉴트리진 (경기도성남시수정구 창업로 42, 630호) filed a patent application (PCT/KR2024/005363) for "COMPOSITION FOR DIRECT CELL LYSIS WHICH CAN BE APPLIED TO VARIOUS SPECIMENS AND ENABLES RAPID NUCLEIC ACID PRETREATMENT, AND PAPER-BASED ONE-STEP ALL-IN-ONE MOLECULAR DIAGNOSTIC PLATFORM HAVING IMPROVED USER CONVENIENCE, USING SAME" on Apr 19, 2024. With publication no. WO/2025/220780, the details related to the patent application was published on Oct 23, 2025.

Notably...